Astrana Health vs Evolent Health
ASTH and EVH side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASTH and EVH compare
Astrana Health is the larger company, worth 3.3 times as much as Evolent Health ($1.8B against $539M).
Astrana Health grew revenue faster over the last twelve months (35.1% versus 14.1% for Evolent Health).
Astrana Health keeps more of each dollar of sales as profit, with a net margin of 1.4% compared with −21.7% at Evolent Health.
Astrana Health scores higher on the StockData Score (12 against 7 for Evolent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASTH | EVH |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $539M |
| Share price | $31.77 | $4.77 |
| Change, 1 year | 33.5% | −5.4% |
| Change, 5 years | −72.0% | −83.5% |
| Beta (5Y) | 1.20 | 0.81 |
| Employees | 3,000 | 4,200 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 4 (better) | 3 |
| Growth score | 5 (better) | 3 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 29.7× | – |
| P/S | 0.5× | 0.2× (better) |
| P/B | 2.1× | 1.4× (better) |
| EV/EBITDA | 12.6× | – |
| P/FCF | 17.8× | – |
| FCF yield | 5.6% | – |
| Fair value | $34.44 | $7.14 |
| Margin of safety | 7.7% | 33.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 35.1% (better) | 14.1% |
| Revenue growth, 5Y average | 35.9% (better) | 15.2% |
| Net income growth (TTM) | 457% | – |
| EPS growth (TTM) | 435% | – |
| EPS growth, 5Y average | −14.6% | – |
| Profitability | ||
| Gross margin | 11.0% | 15.0% (better) |
| Operating margin | 3.1% (better) | −18.5% |
| Net margin | 1.4% (better) | −21.7% |
| FCF margin | 2.5% | – |
| Return on equity | 6.5% (better) | −83.6% |
| Return on invested capital | 5.9% (better) | −23.0% |
| Financial health | ||
| Debt / equity | 1.08 (better) | 2.60 |
| Net debt / EBITDA | 2.87 | – |
| Interest coverage | 1.9× (better) | −6.2× |
| Current ratio | 1.25 | 1.26 (better) |
| Altman Z-score | 2.77 (better) | −0.25 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Payout ratio | 5.1% | – |
| Buyback yield | 1.1% | – |
| Shareholder yield | 1.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 57.7% | 99.3% |
| Held by insiders | 30.7% | 3.3% |
| Insider net buying, 12 months | – | −$329K |
| Short interest, % of float | 7.8% | 9.7% |
Go deeper
- ASTH stock overview
- ASTH income statement
- ASTH valuation and score
- EVH stock overview
- EVH income statement
- EVH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.